Discovery Partnerships with Academia innovative medicines through - - PowerPoint PPT Presentation

Discovery Partnerships with Academia

innovative medicines through integrated partnerships

DPAc: A collaborative approach from GSK

“everyone playing to their strengths”

Deep biology and disease understanding of Academia Drug discovery expertise of GSK

Build integrated partnerships that can translate innovative research into medicines that benefit patients

Key elements of DPAc

• Collaborative partnerships focussed on drug discovery
• Starts at any point from initiation of early screening, finishes with the medicine
• Minimal infrastructure – undertake projects independent of location or disease area
• Access to all GSK drug discovery and development capabilities
• Both sides contribute - looks for a complementary match of skills where GSK can

make a positive contribution to success

• Milestone funding with royalties. If GSK stops then the academic is free to continue

and progress

Focus on the medicine Share in the investment, share in the reward Undertake the best science

Identifying potential DPAc opportunities

What are we looking for:

• Specific opportunities for drug discovery - therapeutics
• Our scope covers almost all disease areas
• Small molecule and biological (protein) modalities
• Early stage discovery projects: its not necessary to have chemical assets or patents
• Therapeutic hypothesis linking target / pathway to disease, built on e.g.:

– genetic evidence, human expression data, in vitro cellular data, in vivo mechanistic models What we are not looking for: (other parts of GSK may be interested!)

• Platforms, vaccines, devices, biomarkers, diagnostics, formulations, basic research
• Diseases of the Developing World (direct link with Tres Cantos Open Lab)
• Other modalities (e.g. nucleoside-based, Cell Therapeutics)
• Completed discovery projects with assets for clinical development
• Repurposing opportunities

4

Who we are

Duncan Holmes European Head DPAc Jon Collins DPAc Leader, NA David Parry Entrepreneur in Residence, NA Mark Bamford DPAc Leader Europe Iain Uings DPAc Leader Europe John Liddle DPAc Leader Europe Colin MacPhee DPAc Leader, NA Mike Bishop DPAc Leader, NA Jakob Busch-Petersen DPAc Leader, NA Ann Walker DPAc Chemist Europe Dennis Yamashita Entrepreneur in Residence, NA Jeremy Griggs DPAc Leader Europe Katherine Widdowson Entrepreneur in Residence, NA Debra Peattie Entrepreneur in Residence, NA Dave Becherer DPAc Leader, NA Stephane Huet DPAc Leader Europe Danuta Mossakowska DPAc Leader Europe

A dedicated team of scientists, each of whom have a proven track record in early drug discovery Your gateway to GSK’s global expertise and resources

Andy Pope DPAc Leader, NA

What we look for

Clear Therapeutic hypothesis A coherent and supportable hypothesis that modulation of target will produce a physiological effect which will be of therapeutic benefit to particular patients Target defined Specific drug target identified, and some understanding of type of pharmacology desired (Exclusive) enabling expertise Academic partner has know-how and/or expertise essential to progressing the target which is not (readily) found elsewhere Tractability Target knowledge suggests that a drug-like molecule can be generated Disease knowledge suggests that opportunity can be evaluated effectively in the clinic Requirement for GSK contribution GSK has capabilities and expertise which will help progress the project to the next milestone

Who it is best suited to Academic researchers who:

• Want to be involved in turning their innovative research into medicines
• Will contribute their own effort and resources to making projects work
• Have recognised expertise in their chosen field
• Bring something unique to the collaboration

What the benefits are

• A single partner from idea to medicine
• A key role in the project
• Working alongside a drug discovery expert from GSK
• Access to a broad array of people, tools and techniques within GSK
• Joint publications and generation of new research tools
• A financial share in the success of a future medicine

What are GSK’s capabilities?

Lead Identification Late Lead Optimisation Early Lead Optimisation Assay Development Target Feasibility

Medicinal chemistry and computational molecular design Preclinical Development (safety, chemistry, pharmacy) Synthetic & analytical chemistry Selectivity screening Encoded Library technology >10 billion compounds HTS capacity 2 million compound set Large scale protein production Flexible, high tech assay platforms PK-PD modelling Biopharm affinity maturation Biopharm discovery platforms

Shared activities between academia and GSK

early stage

Launch & royalties

Phase I Phase II Pre-Clinical Early Drug Discovery Phase III

Candidate Selection FTIH Start PhIII Start Launch Reagent generation Value of GSK support to academic Value of GSK internal contribution Physiological assays

Typical GSK activities

Assay feasibility Tool generation Assay development Screening Chemistry Screening Chemistry DMPK Assay development Chemistry DMPK Safety Pharmacy

Typical academic activities

Physiological assays in vitro and in vivo Physiological assays in vivo models Drug Discovery Initiated Screen Initiated Lead Identified in vitro Lead Identified in vivo

Early Drug Discovery Late Lead Optimisation Lead Identification Early Lead Optimisation Assay Development Target Feasibility

€ € €€ €€€ €€€ € €€ €€ €

Managing the relationship

• Consistent agreement framework to promote rapid project initiation
• Working together – Joint Research Committee
• Joint investment of time/energy/resource to progress the project at

both partner sites

• Strong interactive relationships between project team
• Equitable approach to IP

– Academic will receive commercial rights if GSK terminates the collaboration

Decision making based on emerging data

the decision to stop........for now.....

• Exciting activity for drug-like molecules in recombinant in vitro and in vivo

systems did not translate to patient-derived cell systems

• Focusing together on key decision-making experiments allowed us to rapidly

test our hypothesis

• Further exploratory work required to understand the biology sufficiently to

allow continuation of drug discovery

• The project was returned to Dundee for further definition of underlying

biology and maintaining Dundee’s opportunity to develop a medicine – Commercial rights reverted to Dundee – Key compounds were assigned to Dundee

Discovery Fast Track Challenge

• An opportunity to collaborate together to test our compound collection using our

pharmacological screening platforms to discover active compounds

• We will share key results from the screen to provide you with the best possible

chemical probes to interrogate your translational biological assays

• The researcher provides a novel drug discovery concept that may include assay protocols,

tools, reagents and models

• GSK provides a team of scientists and its state-of-the-art capabilities to scale up and

industrialize assays and data analysis

• The target is screened against GSK compound collections and enabled to find novel quality

pharmacologically active compounds

• Discovery Fast Track is running in Europe in 2014 and we will let you know about the next

Call for Proposals

How does Discovery Fast Track work?

Reagents and Assays High Throughput Screening Encoded Library Technologies Hit Qualification Support

www.gsk.com/discoveryfasttrack

• We are looking for 10 -15 active DPAc collaborations worldwide
• plus preDPAc collaborations
• A team of dedicated scientists within GSK to lead the projects
• Re-personalising the relationships between academia and GSK

contact e-mail: dpac@gsk.com web site: www.dpac.gsk.com

In summary